Advances in targeting the folate receptor in the treatment/imaging of cancers

Chemical Science - Tập 9 Số 4 - Trang 790-810
Marcos Fernández1,2,3, Faiza Javaid1,2,3, Vijay Chudasama1,2,4,3
1Department of Chemistry, University College London, London, UK
2London
3University College London
4Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Lisbon, Portugal

Tóm tắt

The folate receptor (FR) is an important biomarker for many cancers, and its overexpression on tumours can be exploited for targeted therapy, diagnosis and imaging.

Từ khóa


Tài liệu tham khảo

Seitz, 2015, Bioorg. Med. Chem., 23, 2187, 10.1016/j.bmc.2015.02.057

Krall, 2014, Angew. Chem., Int. Ed., 53, 4231, 10.1002/anie.201310709

Valeur, 2017, Drug Discovery Today, 22, 841, 10.1016/j.drudis.2016.12.004

Kularatne, 2009, Mol. Pharm., 6, 780, 10.1021/mp900069d

Bhuniya, 2014, Angew. Chem., Int. Ed., 53, 4469, 10.1002/anie.201311133

Srinivasarao, 2015, Nat. Rev. Drug Discovery, 14, 203, 10.1038/nrd4519

C. V. Galliford and P. S.Low , in Drug Delivery: Principles and Applications , ed. B. Wang , L. Hu and T. J. Siahaan , John Wiley & Sons , 2nd edn, 2016 , pp. 451–474

Quici, 2015, J. Med. Chem., 58, 2003, 10.1021/jm501945w

Mironava, 2013, Toxicol. In Vitro, 27, 882, 10.1016/j.tiv.2013.01.005

Ledermann, 2015, Ann. Oncol., 26, 2034, 10.1093/annonc/mdv250

Lynn, 2015, Blood, 125, 3466, 10.1182/blood-2014-11-612721

Xia, 2009, Blood, 113, 438, 10.1182/blood-2008-04-150789

Paulos, 2004, Adv. Drug Delivery Rev., 56, 1205, 10.1016/j.addr.2004.01.012

Bailly, 2014, Phytochem. Rev., 13, 171, 10.1007/s11101-013-9300-x

Puig-Kröger, 2009, Cancer Res., 69, 9395, 10.1158/0008-5472.CAN-09-2050

Kurahara, 2012, Ann. Surg Oncol., 19, 2264, 10.1245/s10434-012-2263-0

Sun, 2014, Laryngoscope, 124, E312, 10.1002/lary.24606

Shen, 2015, Oncotarget, 6, 14700, 10.18632/oncotarget.3739

Feng, 2011, Arthritis Res. Ther., 13, R59, 10.1186/ar3312

Chen, 2013, Nature, 500, 486, 10.1038/nature12327

Patel, 2016, Mol. Pharm., 13, 1996, 10.1021/acs.molpharmaceut.6b00149

Siwowska, 2017, Mol. Pharm., 14, 523, 10.1021/acs.molpharmaceut.6b01010

Sun, 2015, Colloids Surf., B, 135, 56, 10.1016/j.colsurfb.2015.07.013

Vlahov, 2012, Bioconjugate Chem., 23, 1357, 10.1021/bc2005522

Betzel, 2013, Bioconjugate Chem., 24, 205, 10.1021/bc300483a

Birn, 2005, J. Am. Soc. Nephrol., 16, 608, 10.1681/ASN.2004080711

Simons, 1985, Annu. Rev. Cell Biol., 1, 243, 10.1146/annurev.cb.01.110185.001331

Azzi, 2013, Front Oncol., 3, 1, 10.3389/fonc.2013.00211

Leamon, 2014, Bioconjugate Chem., 25, 560, 10.1021/bc400441s

Cheng, 2013, ACS Appl. Mater. Interfaces, 5, 4389, 10.1021/am401428n

Vineberg, 2014, J. Med. Chem., 57, 5777, 10.1021/jm500631u

Lee, 1996, Biochim. Biophys. Acta, 1312, 237, 10.1016/0167-4889(96)00041-9

Vlahov, 2006, Bioorg. Med. Chem. Lett., 16, 5093, 10.1016/j.bmcl.2006.07.030

Vergote, 2015, Ther. Adv. Med. Oncol., 7, 206, 10.1177/1758834015584763

Bartouskova, 2015, Pteridines, 26, 1, 10.1515/pterid-2014-0013

Ladino, 1997, Int. J. Cancer, 73, 859, 10.1002/(SICI)1097-0215(19971210)73:6<859::AID-IJC16>3.0.CO;2-#

Reddy, 2006, Cancer Chemother. Pharmacol., 58, 229, 10.1007/s00280-005-0151-z

Leamon, 2007, Mol. Pharm., 4, 659, 10.1021/mp070049c

Leamon, 2008, Cancer Res., 68, 9839, 10.1158/0008-5472.CAN-08-2341

Reddy, 2009, Mol. Pharm., 6, 1518, 10.1021/mp900086w

Henne, 2013, Bioorg. Med. Chem. Lett., 23, 5810, 10.1016/j.bmcl.2013.08.113

Alsarraf, 2015, Chem. Commun., 51, 15792, 10.1039/C5CC05294G

Antunes, 2012, Mol. Pharm., 9, 3277, 10.1021/mp300327w

Tranoy-Opalinski, 2014, Eur. J. Med. Chem., 74, 302, 10.1016/j.ejmech.2013.12.045

Paranjpe, 2005, Anticancer Drugs, 16, 763, 10.1097/01.cad.0000172834.78068.7c

Lu, 1999, J. Drug Targeting, 7, 43, 10.3109/10611869909085491

Santos, 2017, Angew. Chem., Int. Ed., 56, 9346, 10.1002/anie.201703492

Li, 2015, Oncol. Rep., 33, 125, 10.3892/or.2014.3593

Dcona, 2017, Bioorg. Med. Chem. Lett., 27, 466, 10.1016/j.bmcl.2016.12.036

Ke, 2013, J. Med. Chem., 56, 8475, 10.1021/jm4009168

Nkepang, 2014, Bioconjugate Chem., 25, 2175, 10.1021/bc500376j

Armstrong, 2013, Gynecol. Oncol., 129, 452, 10.1016/j.ygyno.2013.03.002

Pfisterer, 2006, J. Clin. Oncol., 24, 4699, 10.1200/JCO.2006.06.0913

Bolis, 2001, Gynecol. Oncol., 81, 3, 10.1006/gyno.2001.6151

González-Martín, 2005, Ann. Oncol., 16, 749, 10.1093/annonc/mdi147

Chudasama, 2016, Nat. Chem., 8, 114, 10.1038/nchem.2415

Senter, 2009, Curr. Opin. Chem. Biol., 13, 235, 10.1016/j.cbpa.2009.03.023

Kurkjian, 2013, J. Clin. Oncol., 31, 2573, 10.1200/jco.2013.31.15_suppl.2573

Moore, 2014, J. Clin. Oncol., 32, 5571, 10.1200/jco.2014.32.15_suppl.5571

Schultz, 1995, Oncol. Res., 7, 97

Ross, 1999, Cancer, 85, 348, 10.1002/(SICI)1097-0142(19990115)85:2<348::AID-CNCR12>3.0.CO;2-4

Pan, 2002, Blood, 100, 594, 10.1182/blood.V100.2.594

G. Tapia and I.Díaz-Padilla , in Ovarian Cancer - A Clinical and Translational Update , ed. I. Díaz-Padilla , InTech , Rijeka , 2013 , pp. 205–214

Maeda, 1986, Jpn. J. Cancer Res., 77, 523

Wang, 2015, J. Mater. Chem. B, 3, 296, 10.1039/C4TB01135J

Lu, 2007, Mol. Pharm., 4, 707, 10.1021/mp070058l

Maurer, 2014, J. Nucl. Med., 55, 701, 10.2967/jnumed.113.133074

Naumann, 2013, J. Clin. Oncol., 31, 4400, 10.1200/JCO.2013.49.7685

Morris, 2014, Ann. Oncol., 25, 852, 10.1093/annonc/mdu024

Leamon, 2002, Bioconjugate Chem., 13, 1200, 10.1021/bc0200430

Fisher, 2008, J. Nucl. Med., 49, 899, 10.2967/jnumed.107.049478

Mathias, 1999, Nucl. Med. Biol., 26, 23, 10.1016/S0969-8051(98)00076-6

Wang, 1997, Bioconjugate Chem., 8, 673, 10.1021/bc9701297

Guo, 1999, J. Nucl. Med., 40, 1563

Siegel, 2003, J. Nucl. Med., 44, 700

van Dam, 2011, Nat. Med., 17, 1315, 10.1038/nm.2472

AlJammaz, 2014, Nucl. Med. Biol., 41, 457, 10.1016/j.nucmedbio.2014.03.013

Teng, 2012, Expert Opin. Drug Delivery, 9, 901, 10.1517/17425247.2012.694863

Banerjee, 2001, Semin. Nucl. Med., 31, 260, 10.1053/snuc.2001.26205

O'Shannessy, 2012, Oncotarget, 3, 414, 10.18632/oncotarget.519

Chen, 2012, Mol. Oncol., 6, 360, 10.1016/j.molonc.2011.11.010

Farkas, 2016, Mol. Pharm., 13, 1979, 10.1021/acs.molpharmaceut.6b00143

Rahmim, 2008, Nucl. Med. Commun., 29, 193, 10.1097/MNM.0b013e3282f3a515

Kratz, 2002, J. Med. Chem., 45, 5523, 10.1021/jm020276c

Müller, 2013, J. Nucl. Med., 54, 124, 10.2967/jnumed.112.107235

Müller, 2012, J. Nucl. Med., 53, 1951, 10.2967/jnumed.112.107540

Müller, 2014, Eur. J. Nucl. Med. Mol. Imaging, 41, 476, 10.1007/s00259-013-2563-z

Müller, 2014, Pharmaceuticals, 7, 353, 10.3390/ph7030353

Müller, 2013, J. Nucl. Med., 54, 2168, 10.2967/jnumed.113.123810

Müller, 2014, J. Nucl. Med., 55, 1658, 10.2967/jnumed.114.141614

Feng, 2013, Anal. Chem., 85, 6530, 10.1021/ac401377n

Zhang, 2012, Nanotechnology, 23, 1

Chen, 2006, Curr. Org. Chem., 10, 477, 10.2174/138527206776055312

Shi, 2012, Chem. Commun., 48, 8732, 10.1039/c2cc33366j

Shi, 2012, Angew. Chem., Int. Ed., 51, 6432, 10.1002/anie.201202533

Jia, 2010, Chem.–Eur. J., 16, 6638, 10.1002/chem.200902660

Kim, 2011, Chem. Commun., 47, 3195, 10.1039/c0cc05005a

Zhang, 2011, Angew. Chem., Int. Ed., 50, 6851, 10.1002/anie.201100769

Kim, 2010, J. Am. Chem. Soc., 132, 260, 10.1021/ja906730d

Lu, 2009, Angew. Chem., Int. Ed., 48, 4785, 10.1002/anie.200901479

Han, 2015, Am. J. Respir. Cell Mol. Biol., 53, 50, 10.1165/rcmb.2014-0289OC

Nagai, 2010, Clin. Exp. Immunol., 161, 348, 10.1111/j.1365-2249.2010.04182.x

Varghese, 2007, Mol. Pharm., 4, 679, 10.1021/mp0700615

Müller, 2008, J. Nucl. Med., 49, 310, 10.2967/jnumed.107.045856

Jager, 2014, J. Nucl. Med., 55, 1945, 10.2967/jnumed.114.143180